Literature DB >> 9231977

Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunisation with FIV vaccines.

M C Tellier1, J Soos, R Pu, D Pollock, J K Yamamoto.   

Abstract

Vaccine protection has been achieved in cats against experimental infection with feline immunodeficiency virus (FIV). Such protection has been attributed to FIV-specific humoral immunity, as well as cellular immunity of unknown mechanism(s). Since cell-mediated immunity plays a crucial role in the clearance of viral infections, this study evaluated the role of FIV-specific CTL in vaccine prophylaxis. Cats were immunised with inactivated FIV vaccines, reported to have > 90% vaccine efficacy. Significant levels of specific CTL activity were detected following the third immunisation. CTL activity persisted for several months and could be enhanced through a booster immunisation. The levels of CTL activity were comparable to those induced by a recombinant canarypoxvirus based FIV vaccine. These results suggest a possible role for CTL-mediated immunity in vaccine protection against FIV infection in cats.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9231977     DOI: 10.1016/s0378-1135(97)00081-3

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  8 in total

1.  Phylogenetic analyses of Texas isolates indicate an evolving subtype of the clade B feline immunodeficiency viruses.

Authors:  Eric A Weaver; Ellen W Collisson; Margaret Slater; Guan Zhu
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  Anti-feline immunodeficiency virus (FIV) soluble factor(s) produced from antigen-stimulated feline CD8(+) T lymphocytes suppresses FIV replication.

Authors:  I S Choi; R Hokanson; E W Collisson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.

Authors:  B Poon; J T Safrit; H McClure; C Kitchen; J F Hsu; V Gudeman; C Petropoulos; T Wrin; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.

Authors:  B Poon; J F Hsu; V Gudeman; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.

Authors:  C M Leutenegger; F S Boretti; C N Mislin; J N Flynn; M Schroff; A Habel; C Junghans; S A Koenig-Merediz; B Sigrist; A Aubert; N C Pedersen; B Wittig; H Lutz
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1.

Authors:  K Grovit-Ferbas; J F Hsu; J Ferbas; V Gudeman; I S Chen
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 8.  FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review.

Authors:  E W Uhl; T G Heaton-Jones; R Pu; J K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2002-12       Impact factor: 2.046

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.